{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107353","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.731719+00:00","generated_at":"2026-05-16T23:40:44.757462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Therapeutics Q3 net loss widens to $14.6M; cash $167.2M; pipeline updates","bullets":["Net loss $14.6M in Q3 2025 vs $7.6M in Q3 2024; total revenue $3.3M vs $4.3M.","Cash, equivalents and marketable securities $167.2M as of Sep 30, 2025, funding into H2 2028.","Positive Phase 2a results for ATI-2138 in AD; Phase 2 trial in additional indication expected H1 2026.","Top line results for bosakitug (Phase 2 AD) expected H2 2026; ATI-052 Phase 1b POC in asthma/AD expected H1 2026.","R&D expenses rose to $13.0M (vs $6.0M) driven by clinical and preclinical activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107353","json":"https://secwatch.observer/filing/0001104659-25-107353.json","markdown":"https://secwatch.observer/filing/0001104659-25-107353.md","text":"https://secwatch.observer/filing/0001104659-25-107353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/0001104659-25-107353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/acrs-20251106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:40:44.757462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}